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Peptidomimetic inhibitors of N-myristoyltransferase
from human malaria and leishmaniasis parasites†
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N-Myristoyltransferase (NMT) has been shown to be essential in
Leishmania and subsequently validated as a drug target in Plasmo-
dium. Herein, we discuss the use of antifungal NMT inhibitors as a
basis for inhibitor development resulting in the ﬁrst sub-micro-
molar peptidomimetic inhibitors of Plasmodium and Leishmania
NMTs. High-resolution structures of these inhibitors with Plasmo-
dium and Leishmania NMTs permit a comparative analysis of
binding modes, and provide the ﬁrst crystal structure evidence for
a ternary NMT-Coenzyme A/myristoylated peptide product
complex.
Malaria and leishmaniases, infectious diseases caused by Plas-
modium and Leishmania respectively, rank among the world’s
most important public health challenges. These diseases
result in high mortality and morbidity; moreover, they impose
a severe economic burden on aﬀected countries, mainly in
Africa. Of the Plasmodium genus, P. falciparum is the most
deadly, accounting for over 1 million deaths in 2010, and
P. vivax is the most widespread.1 Although malaria-related
deaths have reduced by 30% in recent years, resistance to
current anti-malarial drugs presents an ongoing challenge,
highlighting the need to identify and develop safer and prefer-
ably less resistance-prone treatments.2 Visceral leishmaniasis,
the most deadly of the leishmaniases, is caused by L. donovani,
and accounts for ∼50 000 deaths per annum.3 Currently avail-
able treatments can be expensive, possess a relatively narrow
therapeutic window or are subject to resistance, highlighting
the need for better drugs.4
N-Myristoyltransferase (NMT), an enzyme that modifies
protein substrates by attaching myristate (14 : 0) to an N-term-
inal glycine via an amide bond, has been proposed as a poten-
tial therapeutic target in both malaria and leishmaniasis5,6
and has recently been validated as viable drug target for
human malaria.7 Catalysis is thought to commence with
ordered binding of S-myristoyl-coenzyme A (Myr-CoA) followed
by the protein substrate, transfer of myristate and ordered
release of myristoylated protein and free coenzyme A.8 Myris-
toylation is important for protein–protein and protein–mem-
brane interactions; the essentiality of NMT in the viability of
both fungal and protozoan organisms9,10 makes NMT an inter-
esting target for the development of antifungal and anti-para-
sitic drugs.11,12
Peptidomimetic inhibitors based on peptide substrates of
NMT have previously been developed against Candida albicans
NMT (CaNMT),13,14 but have yet to be reported in the context
of parasitic NMT inhibition. CaNMT shares 44% and 43%
sequence identity with P. vivax and L. donovani NMTs (PvNMT,
LdNMT) respectively; we reasoned that inhibitors of Plasmo-
dium and Leishmania NMTs might be acquired through a
‘piggy-back’ approach, using CaNMT peptidomimetics as a
platform.15 Reported CaNMT peptidomimetic inhibitors were
based on residues 1–7 at the N-terminus of C. albicans ADP
ribosylation factor protein, GLYASKL. Subsequently, the
N-terminal amine and Ser5-Lys6 dipeptide, a motif also seen in
known substrates of Plasmodium and Leishmania NMTs, were
identified as making important binding contributions.5,7 We
therefore chose to employ a similar peptidomimetic scaﬀold
based on the Ser-Lys motif, substituting the first four amino
acids with an alkyl chain capped by a group that mimics the
N-terminal amine, and the C-terminal leucine with a hydro-
phobic motif (Fig. 1). Our inhibitor library design incorporated
modifications at the C- and N-termini with the objective of
exploring contacts at both ends of the scaﬀold. Peptidomi-
metics were synthesized through a combination of solid and
solution phase chemistries. N-Boc-protected amino and 1H-
imidazol-1-yl acids were coupled to an O-t-butyl serine/N-Boc
lysine dipeptide linked via a chlorotrityl (Route A, Scheme 1)
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or hydrazinobenzoyl linker (Route B, Scheme 1) to polystyrene
resin. In the case of chlorotrityl resins, intermediates were
cleaved from the resin with 0.5% TFA–DCM and coupled to
the requisite amine (Scheme 1). C-terminal amide and acid
analogs were synthesized using similar chemistry on Rink
amide and Wang resins, respectively.
Switching to a hydrazinobenzoyl linker eliminated the need
for solution phase chemistry to couple the C-terminal
amine;16 thus one-pot treatment of the peptidyl-resin in the
presence of copper(II) acetate and excess of the appropriate
amine led to simultaneous cleavage of the peptide from the
resin and formation of the corresponding protected
peptidomimetic.
Final products were deprotected by treatment with TFA and
purified by semi-preparative RP-HPLC-MS to give a small
library of peptidomimetic inhibitors. Modifications at the
N-terminus were approached by two distinct structural permu-
tations: varying the N-terminal motif (R1, Fig. 1) to optimize
basicity, and varying the alkyl linker length (n) to determine
the optimal distance between the N-terminal amide of the
serine and the N-terminal nitrogen atom of R1 (Fig. 1). The
N-terminal motif of the peptidomimetic was expected to inter-
act directly with the C-terminal carboxylate leucine of the
enzyme, a critical residue for catalytic activity responsible for
the activation of the N-terminal amine of the protein/peptide
substrate.17
2-Methylimidazolyl analogues were synthesized building on
the hypothesis that 2-methylimidazole (pKa ∼ 7.9)18 is a
reasonable mimetic for N-terminal Gly in the peptide substrate
(pKa ∼ 8.0).19 To cover a range of basicity, imidazolyl (pKa ∼
7.0) and amine analogues (pKa ∼ 10.0) were also synthesized,
each exploring a range of chain lengths (n) (Table 1). To probe
versatility at the C-terminus, primary amides, carboxylic acids,
2-cyclohexylethyl and 2-(1-cyclohexenyl)ethyl amides were
incorporated. Using a previously reported fluorogenic assay,20
inhibitors were tested against the parasitic enzymes and
HsNMT1 in order to explore their selectivity against a relevant
host enzyme. Previously reported imidazolyl-derived peptido-
mimetics (1–4) shown to possess low-µM activities against
CaNMT14 displayed little or no activity against the parasitic
enzymes used in this study. Slightly improved potency was
observed for 2-methylimidazolyl analogues (5–8) across all
chain lengths tested, and particularly 6, which provided sub-
micromolar inhibition for L. donovani NMT. However, amine 9
showed markedly improved inhibition against the NMTs of
P. vivax (PvNMT), L. donovani (LdNMT) and H. sapiens
(HsNMT1) (Table 1). Reduction of the alkyl chain length from
n = 10 to 9 gave compound 10, which is the most potent
L. donovani NMT inhibitor reported to date (LdNMT IC50 = 24
nM). It also showed somewhat lower activity against HsNMT1
(IC50 = 60 nM) and PvNMT (680 nM). Further reduction of the
chain length (11 and 12, n = 8 and 7, respectively) led to loss of
detectable activity against Plasmodium NMTs and significant
loss of activity against LdNMT and HsNMT1. Comparing
N-terminal variations with similar chain length, the potency of
amine 10 against LdNMT was over 400- and 20-fold higher
than 2 (1H-imidazol-1-yl) and 6 (2-methyl-1H-imidazol-1-yl),
respectively.
Fig. 1 Peptidomimetic scaﬀold targeting parasite NMTs. R1 and R2 represent points of variation at the N- and C-termini.
Scheme 1 Synthetic routes to peptidomimetics. Reagents and conditions. (a) Fmoc-Ser(t-Bu)-OH, HBTU, DIPEA, DMF; (b) 20% piperidine–DMF;
(c) R3COOH, HATU, DIPEA, DMF; (d) 0.5% TFA in DCM; (e) R4NH2, HATU, DIPEA, DMF; (f ) TFA–TIPS–H2O (95 : 2.5 : 2.5); (g) Fmoc-Lys(Boc)-OH,
HBTU, DIPEA, DMF; (h) Cu(OAc)2, pyridine, DCM, R4NH2.
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We next probed the SAR around the amino group of 10, and
found that N-methylation (to give 13) led to significant
reduction in potency, whilst replacing the flexible N-terminal
chain with an acetyl group (to give 14) resulted in no observa-
ble activity.
We further probed the importance of charge at the N-termi-
nus by substituting a hydroxyl for the amine and observed a
more modest loss in activity of >100 and 1000 folds in Leishma-
nia and Human NMTs respectively (46, ESI,† accession code:
4c7i). These observations are consistent with our expectation
that the N-terminal moiety of the inhibitor is involved in a
strong electrostatic interaction with the C-terminal carboxylate
of the enzyme, an interaction likely to be sensitive to changes
in inhibitor structure and charge.21 Amongst inhibitors with a
C-terminal 2-(1-cyclohexenyl)ethanamide (15–20, Table 1), 16
showed fair activity against LdNMT, HsNMT1 and PvNMT,
whilst others showed little (15) or no activity (17–20) against
the tested enzymes up to the highest concentration tested
(100 µM). This 10–20 fold drop in activity relative to 2-cyclohexyl-
ethanamide suggests that the presence of a single unsaturated
bond in the pocket occupied by the cyclohexenyl ring deters
important interactions with the enzyme, presumably by modi-
fying ring conformation. Inhibitors with C-terminal carbox-
amides and carboxylic acids (21–26) showed minimal activity
across the enzymes tested, with the exception of 22 (Table 1) with
an n = 9 chain length. Overall, an ideal chain length of n = 9
and a C-terminal cyclohexyl ring was observed to be the most
potent combination irrespective of the enzyme tested, and at
the N-terminus, inhibitor potencies increased in the order:
1H-imidazol-1-yl < 2-methyl-1H-imidazol-1-yl < –NH2.
To determine the binding mode of 10, a ternary complex
with PvNMT and S-(2-oxo)pentadecyl-CoA (NHM, a non-hydro-
lysable Myr-CoA analogue) was crystallized and solved to a
high resolution of 1.38 Å (accession code: 4c68, Fig. 2A). 10
sits in the peptide-binding pocket, and mimics the key recog-
nition elements involved in binding the parent peptide
(GLYASKL, Fig. 2B and C). The N-terminal amine electrostati-
cally interacts with the carboxylate of Leu410 whilst the
hydroxyl group of the serine hydrogen bonds to the His213
side chain. In addition, there are ionic interactions between
the amino group of the lysine and three neighboring aspartic
acid residues (Asp98, Asp100, Asp385), all of which are con-
served in equivalent residues CaNMT. The aliphatic chain on
the N-terminus and the N-terminal amino group of the inhibi-
tor are guided by the peptide binding channel to the C-term-
inal residue of PvNMT–Leu410. For comparison, a ternary
structure of 10 with the native substrate, Myr-CoA, in L. major
NMT (97% sequence identity to L. donovani) was solved and
refined to a resolution of 1.41 Å (accession code: 4c7h). As
expected, the mode of binding of 10 in L. major is very similar
to that in P. vivax.
Unexpectedly, the electron maps indicated a mixture of
ligand structures such that ∼20% of the electron density rep-
resents a N-myristoylated 10 product complex with the CoA by-
Table 1 Structures and enzyme aﬃnities for peptidomimetics synthesized in this studya
R1 n R2
IC50 (µM)
PvNMT PfNMT LdNMT HsNMT1
1 1H-Imidazol-1-yl 10 2-Cyclohexylethanamine >100 >100 25.8 ± 8.2 47.6 ± 3.8
2 1H-Imidazol-1-yl 9 2-Cyclohexylethanamine >100 >100 10.6 ± 1.6 44.0 ± 7.1
3 1H-Imidazol-1-yl 8 2-Cyclohexylethanamine >100 >100 16.7 ± 2.5 >100
4 1H-Imidazol-1-yl 7 2-Cyclohexylethanamine >100 >100 34.8 ± 3.7 >100
5 2-Methyl-1H-Imidazol-1-yl 10 2-Cyclohexylethanamine >100 >100 >100 21.8 ± 0.8
6 2-Methyl-1H-Imidazol-1-yl 9 2-Cyclohexylethanamine >100 >100 0.63 ± 0.01 7.92 ± 0.83
7 2-Methyl-1H-Imidazol-1-yl 8 2-Cyclohexylethanamine >100 >100 3.42 ± 0.34 49.9 ± 10.6
8 2-Methyl-1H-Imidazol-1-yl 7 2-Cyclohexylethanamine >100 >100 1.46 ± 0.22 82.2 ± 14.0
9 H2N– 10 2-Cyclohexylethanamine 1.04 ± 0.01 >100 0.14 ± 0.01 0.34 ± 0.03
10 H2N– 9 2-Cyclohexylethanamine 0.68 ± 0.08 24.3 ± 3.4 0.024 ± 0.003 0.06 ± 0.003
11 H2N– 8 2-Cyclohexylethanamine >100 >100 2.01 ± 0.30 7.68 ± 0.86
12 H2N– 7 2-Cyclohexylethanamine >100 >100 1.39 ± 0.18 6.75 ± 0.45
13 MeNH– 9 2-Cyclohexylethanamine >100 >100 0.21 ± 0.01 0.73 ± 0.10
14 H3C– 0 2-Cyclohexylethanamine >100 >100 >100 >100
15 H2N– 10 2-(1-Cyclohexenyl)-ethanamine 12.9 ± 1.07 >100 6.60 ± 1.28 2.30 ± 0.14
16 H2N– 9 2-(1-Cyclohexenyl)-ethanamine 3.55 ± 0.38 >100 0.44 ± 0.04 0.67 ± 0.04
17 1H-Imidazol-1-yl 10 2-(1-Cyclohexenyl)-ethanamine >100 >100 >100 >100
18 1H-Imidazol-1-yl 9 2-(1-Cyclohexenyl)-ethanamine >100 >100 >100 >100
19 2-Methyl-1H-Imidazol-1-yl 10 2-(1-Cyclohexenyl)-ethanamine >100 >100 >100 >100
20 2-Methyl-1H-Imidazol-1-yl 9 2-(1-Cyclohexenyl)-ethanamine >100 >100 28.0 ± 2.5 >100
21 H2N– 10 –NH2 >100 >100 13.3 ± 2.0 5.40 ± 0.41
22 H2N– 9 –NH2 22.9 ± 3.5 >100 1.36 ± 0.20 1.36 ± 0.29
23 H2N– 8 –NH2 >100 >100 27.1 ± 2.6 33.1 ± 2.5
24 H2N– 7 –NH2 >100 >100 61.9 ± 4.7 >100
25 H2N– 10 –OH >100 >100 86.7 ± 10.4 39.2 ± 2.0
26 H2N– 9 –OH >100 >100 >100 92.1 ± 17.6
a Enzymatic activities of recombinant P. vivax, P. falciparum and L. donovani NMT in the presence of peptidomimetic inhibitors expressed as IC50
values. These values are a mean of duplicate or triplicate experiments.
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product in LmNMT (Fig. 2D). This is the only structural evi-
dence for a product complex in any N-myristoyltransferase,
and captures and supports the proposed mechanism of action
of NMT just prior to regeneration of the active enzyme. Kinetic
experiments were performed to study 10 both as a potential sub-
strate and as an NMT inhibitor. As anticipated from the struc-
tures above, 10 appeared to behave as a peptide-competitive
inhibitor but no substrate characteristics were detected in the
assay up to 40 µM (Fig. S3 and S4, ESI†). The N-myristoylation
of 10 observed above therefore presumably occurs within the
crystal where all reagents are present at high eﬀective concen-
trations, and turnover is blocked by limited egress of products.
To probe the degree to which 10 acts as a true peptidomi-
metic, we investigated the potential to switch from inhibitor to
a peptidomimetic substrate. A glycine (27) or alanine (28)
residue was incorporated in the N-terminal extension; 27 was
found to be a substrate for Leishmania NMT with KM = 1.3 µM,
which compares favorably with the aﬃnity of a CaNMT octa-
peptide substrate (GLYASKLS-NH2, KM = 0.6 µM)
13 and the
model peptide substrate used for inhibitor assays
(GSNKSKPK-NH2 H. sapiens p60
src
(2–9), KM = 22.6 µM), although
with a considerably reduced Vmax (Fig. S4, ESI†). 28, on the
other hand, showed no detectable substrate activity. In native
NMT substrates, N-terminal Gly is preferred to the exclusion of
all other residues, with relatively non-sterically demanding
residues such as alanine. The substrate properties of 27 and 28
suggest a highly peptidomimetic binding conformation, and
imply that steric factors play a key role in the progression of
the catalytic cycle, dictating the approach of the N-terminal
amine to the C-terminal leucine of the enzyme.
The potent inhibitors discovered in this study showed low
specificity for the Plasmodium NMTs in comparison to Leish-
mania and human NMTs. A sequence alignment of residues
within 6 Å of the catalytic sites of Leishmania and Human
NMTs (see ESI†) showed a 74% similarity between both
enzymes. In comparison, a similar alignment of Human and
Plasmodium NMTs showed a 53% similarity between residues.
The catalytic site of Leishmania NMT is, therefore, thought to
show more comparability to the Human enzyme than the Plas-
modium NMTs. Additionally, there are key residues, such as
Arg231 (LdNMT) and Lys308 (Human NMT), capable of
forming hydrogen bond interactions which would otherwise
be impossible in the Plasmodium NMTs (Gly225). It is thought
that the presence of such basic centres could increase the
binding and subsequently, potencies of these inhibitors for
Leishmania and human NMTs.
Fig. 2 (A) Co-crystal structure of PvNMT (chain C; grey surface) with bound NHM (magenta) and 10 (green), colored by atom. (B) Superimposition
of peptide substrate (GLYASKL, blue) with 10 (green, 4c68) in PvNMT. The peptide was modeled to maximize overall structural similarity while main-
taining peptide geometric restraints. (C) Ternary structure of 10 (green, sticks) and non-hydrolysable Myr-CoA (partially shown; magenta; sticks) in
PvNMT (4c68) showing main recognition interactions between 10 and the enzyme. Residues within 4 Å of 10 are shown in blue. Polar interactions
and their distances (in Å) are shown as dashed lines. (D) Reﬁned electron density map showing the mixture of structures of 10 and myr-10 (yellow) in
a ball and stick representation observed in LmNMT (4c7h). The ﬁgure shows the mixture of ligands present in the ﬁnal reﬁned model (80% reactants
– purple and red and 20% products – green and yellow) shown in a ball-and-stick representation to aid identiﬁcation. Electron density ﬁgures were
made using the program CCP4 mg.22 See Fig. S2 (ESI†) for more details.
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Unusually, the inhibitors in this study showed a higher
specificity for P. vivax NMT in comparison to P. falciparum
NMT. An alignment of the primary sequences of both enzymes
(see ESI†) highlighted four diﬀering residues within 6 Å of the
peptide binding pocket: Ile102, Tyr212, Ser228, Tyr334
(PvNMT) and Val102, Phe212, Cys228 and Phe334 (PfNMT). Of
these diﬀerences, the replacement of Y334 to F334 in PfNMT
constitutes a structural change in the peptide pocket that
could lead to a loss of potential hydrogen bond interactions
within the catalytic site. The reason for the specificity for
PvNMT is unclear; however, we propose that the loss of such
vital hydrogen bonds in PfNMT could be responsible for this
observation.
Conclusions
Using antifungal NMT inhibitors as a platform, we developed
inhibitors of Plasmodium and Leishmania NMTs, resulting in
the identification of an inhibitor, 10, with sub-micromolar
potency against P. vivax and L. donovani NMTs, and the most
potent Leishmania donovani NMT inhibitor reported to date.
High-resolution ternary structures of compound 10 were
achieved in both PvNMT and LmNMT, with the latter structure
revealing the first structural evidence supporting the proposed
catalytic cycle of NMT. Although 10 shows moderate selectivity
against human NMT, the structures presented here may serve
as a useful tool to enable a structure-guided design of more
potent and selective parasitic inhibitors.
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